Open Access Article
Tu-Quyen Thi Tran‡
ab,
Duong Hoang Trinhc,
Binh Thi Dieu Trinhab,
Dzung Ngoc Buiab,
Lien-Hoa Dieu Nguyenab and
Phuong Thu Tran
*ab
aFaculty of Chemistry, University of Science – Ho Chi Minh City – Vietnam, 227 Nguyen Van Cu Street, District 5, Ho Chi Minh City, 700000, Vietnam. E-mail: ttphuong@hcmus.edu.vn
bVietnam National University – Ho Chi Minh City, Linh Trung Ward, Thu Duc City, Ho Chi Minh City, 700000, Vietnam
cInstitute of Drug Quality Control, 200 Co Bac Street, District 1, Ho Chi Minh City, 700000, Vietnam
First published on 11th June 2024
Four new mexicanolide-type limonoids, swietemicrolides A–D (1–4), together with three known compounds (5–7) were isolated from an ethyl acetate extract of the bark of Swietenia microphylla. 1 and 2 had 1,8-hemiacetal systems whilst 3 and 4 shared hexacyclic skeletons consisting of three fused five-membered rings. The structures of the isolated compounds were determined using spectroscopic methods. The five limonoids (1–5) were tested in vitro for their cytotoxic effects against two human cancer cell lines (KB carcinoma and A549 lung cancer cells) and α-glucosidase inhibitory activity. None of them showed significant cytotoxic activity, however, swietemicrolide C (3) exhibited strong effect towards α-glucosidase. Moreover, a possible biosynthetic pathway for compounds 1–4 was proposed to support a comprehensive understanding of the configurations of the new limonoids.
In the present study, we reported the isolation and structural identification of seven compounds, consisting of four new mexicanolide-type limonoids, named swietemicrolides A–D (1–4), along with a known andirobin-type limonoid characterized as swiemahogin A (5),19 a steroid, β-sitosterol-3-O-β-D-glucopyranoside (6)20 and homovanillyl alcohol (7)21 from the bark (Fig. 1). Compounds 3 and 4 were proved to possess a grandifotane scaffold, a complex hexacyclic skeleton containing three fused five-membered rings, which has been seen in a unique compound, grandifotane A, so far.22 In addition, the five limonoids (1–5) were evaluated for their in vitro biological potency comprising cytotoxic activities against KB carcinoma, A549 lung cancer cell lines and α-glucosidase inhibition.
:
1, v/v) yielded nine fractions (A1–9). Purification of fraction A2 using CC (silica gel, n-hexane–EtOAc) furnished 4 (6.3 mg). Fraction A4 was separated by CC [silica gel, n-hexane–(CHCl3–acetone 9
:
1, v/v)] to give eight fractions (A4.1–8). Repeated CC of fractions A4.3, A4.6, A4.7 on silica gel (n-hexane–EtOAc) produced 3 (32.3 mg), 1 (75.8 mg) and 2 (11.8 mg). Similarly, fractions A5 and A7 were repeatedly subjected to silica gel CC (n-hexane–EtOAc) to obtain 7 (12.9 mg) and 5 (43.4 mg), respectively. Continuous CC of fraction E5.2B (454 mg) on silica gel (n-hexane–EtOAc) led to the isolation of 6 (297.5 mg).
ε): 208 (3.74) nm; IR (KBr) νmax: 3478, 2951, 2892, 1742, 1436, 1372, 1301, 1222, 1108, 1027 cm−1; 1H NMR (CDCl3, 500 MHz) and 13C NMR (CDCl3, 125 MHz): see Tables 1 and 2, respectively; HREIMS m/z 661.2483 [M − H]− (calcd for C33H41O14 661.2502).
| No. | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
| 1 | — | — | — | — |
| 2 | — | — | — | — |
| 3 | 5.52 s | 4.93 br s | 5.36 s | 5.44 s |
| 5 | 2.73 d (10.1) | 2.71 d (10.2) | 2.68 dd (10.4, 2.5) | 2.73 d (4.8) |
| 6 | Ha: 2.66 d (16.7) | Ha: 2.66 d (16.5) | Ha: 2.44 d (10.3) | 5.19 d (4.9) |
| Hb: 2.35 dd (16.6, 10.1) | Hb: 2.33 dd (16.6, 10.3) | Hb: 2.42 d (2.4) | ||
| 9 | 2.38 d (12.0) | 2.46 d (11.9) | 2.35 dd (11.1, 2.5) | 1.77 dd (5.5, 1.9) |
| 11 | 5.06 td (11.4, 4.0) | 5.05 td (11.4, 3.9) | 5.10 td (11.3, 4.5) | Ha: 1.88 ddd (13.3, 5.4, 3.5) |
| Hb: 1.64 td (13.5, 2.9) | ||||
| 12 | Ha: 2.25 dd (13.7, 4.0) | Ha: 2.25 dd (13.7, 3.7) | Ha: 2.09 dd (13.7, 4.3) | Ha: 1.83 dd (12.5, 2.9) |
| Hb: 1.65 dd (13.8, 10.8) | Hb: 1.67 dd (13.4, 11.1) | Hb: 1.92 dd (13.7, 11.6) | Hb: 1.41 dd (12.3, 3.7) | |
| 14 | — | — | — | 2.35 br d (7.2) |
| 15 | Ha: 3.05 d (19.0) | 3.01 s | Ha: 3.10 d (18.4) | Ha: 2.89 dd (19.3, 7.4) |
| Hb: 2.82 d (19.1) | Hb: 2.82 d (18.4) | Hb: 2.82 br d (19.2) | ||
| 17 | 5.34 s | 5.39 s | 5.55 s | 5.55 s |
| 18 | 0.93 s | 0.92 s | 0.99 s | 1.05 s |
| 19 | 1.19 s | 1.23 s | 1.10 s | 1.24 s |
| 21 | 7.82 s | 7.75 s | 7.78 s | 7.45 br s |
| 22 | 6.77 s | 6.67 br s | 6.71 d (0.8) | 6.37 dd (1.8, 0.9) |
| 23 | 7.44 br s | 7.41 br s | 7.46 t (1.7) | 7.46 t (1.7) |
| 28 | 1.34 s | 1.32 s | 1.24 s | 1.42 s |
| 29 | 0.72 s | 0.71 s | 0.96 s | 0.96 s |
| 30 | Ha: 2.89 d (14.8) | Ha: 2.80 d (14.5) | Ha: 2.39 d (11.0) | Ha: 2.28 dd (11.3, 2.0) |
| Hb: 1.91 d (15.6) | Hb: 1.99 m | Hb: 2.31 dd (11.0, 2.5) | Hb: 2.24 d (11.2) | |
| 2-OAc | 2.11 s | — | — | — |
| 3-OAc | 2.13 s | 2.10 s | 2.08 s | 2.09 s |
| 6-OAc | — | — | — | 2.16 s |
| 7-OMe | 3.67 s | 3.66 s | 3.69 s | 3.79 s |
| 11-OAc | 1.93 s | 1.91 s | 2.02 s | — |
ε) 209 (3.14) nm; IR (KBr) νmax 3446, 2921, 2851, 1740, 1636, 1457, 1374, 1228, 1111, 1028 cm−1; 1H NMR (CDCl3, 500 MHz) and 13C NMR (CDCl3, 125 MHz): see Tables 1 and 2, respectively; HREIMS m/z 619.2385 [M − H]− (calcd for C33H39O14 619.2396).
| No. | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
| 1 | 108.9, C | 109.7, C | 171.6, C | 173.1, C |
| 2 | 94.4, C | 81.0, C | 66.1, C | 66.3, C |
| 3 | 75.7, CH | 81.3, CH | 76.4, CH | 76.4, CH |
| 4 | 39.9, C | 38.7, C | 44.6, C | 45.7, C |
| 5 | 39.4, CH | 39.6, CH | 47.2, CH | 51.8, CH |
| 6 | 32.1, CH2 | 32.3CH2 | 32.3, CH2 | 72.1, CH |
| 7 | 174.1, C | 174.3, C | 172.6, C | 170.2, C |
| 8 | 81.4, C | 82.6, C | 94.0, C | 92.0, C |
| 9 | 58.0, CH | 58.5, CH | 55.8, CH | 55.2, CH |
| 10 | 47.6, C | 44.9, C | 51.1, C | 50.5, C |
| 11 | 69.0, CH | 69.2, CH | 69.0, CH | 21.8, CH2 |
| 12 | 36.2, CH2 | 36.0, CH2 | 34.0, CH2 | 34.2, CH2 |
| 13 | 41.8, C | 41.8, C | 41.2, C | 35.3, C |
| 14 | 71.3, C | 71.3, C | 71.3, C | 42.4, CH |
| 15 | 37.0, CH2 | 36.9, CH2 | 37.0, CH2 | 28.2, CH2 |
| 16 | 169.0, C | 170.1, C | 168.0, C | 169.3, C |
| 17 | 77.8, CH | 78.0, CH | 77.8, CH | 77.8, CH |
| 18 | 15.4, CH3 | 15.7, CH3 | 15.9, CH3 | 22.5, CH3 |
| 19 | 22.8, CH3 | 21.8, CH3 | 22.8, CH3 | 22.7, CH3 |
| 20 | 120.4, C | 120.5, C | 120.2, C | 121.1, C |
| 21 | 141.7, CH | 141.6, CH | 141.5, CH | 140.6, CH |
| 22 | 110.2, CH | 110.2, CH | 109.8, CH | 109.5, CH |
| 23 | 143.0, CH | 142.8, CH | 143.3, CH | 143.6, CH |
| 28 | 22.5, CH3 | 22.5, CH3 | 26.7, CH3 | 27.5, CH3 |
| 29 | 24.5, CH3 | 24.4, CH3 | 27.3, CH3 | 27.9, CH3 |
| 30 | 41.1, CH2 | 41.9, CH2 | 41.7, CH2 | 40.0, CH2 |
| 2-OAc | 175.3, C | — | — | — |
| 22.3, CH3 | — | — | — | |
| 3-OAc | 170.6, C | 171.5, C | 170.1, C | 170.1, C |
| 21.10, CH3 | 21.12, CH3 | 20.9, CH3 | 20.9, CH3 | |
| 6-OAc | — | — | — | 170.3, C |
| — | — | — | 21.0, CH3 | |
| 7-OCH3 | 52.2, CH3 | 52.1, CH3 | 52.1, CH3 | 52.9, CH3 |
| 11-OAc | 169.8, C | 169.8, C | 169.8, C | — |
| 21.08, CH3 | 21.07, CH3 | 21.2, CH3 | — |
ε): 208 (2.95) nm; IR (KBr) νmax: 3502, 2960, 2920, 2850, 1793, 1741, 1541, 1457, 1363, 1234, 1045, 1029 cm−1; 1H NMR (CDCl3, 500 MHz) and 13C NMR (CDCl3, 125 MHz): see Tables 1 and 2, respectively; HREIMS m/z 647.2318 [M + HCOO]− (calcd for C32H39O14 647.2345).
ε): 208 (3.17), 283 (1.89) nm; IR (KBr) νmax: 3447, 2970, 2940, 2360, 1791, 1743, 1541, 1457, 1374, 1232, 1119, 1044 cm−1; 1H NMR (CDCl3, 500 MHz) and 13C NMR (CDCl3, 125 MHz): see Tables 1 and 2, respectively; HREIMS m/z 587.2521 [M + H]+ (calcd for C31H39O11 587.2487).
:
3 in 3–5 days and incubated at 37 °C under 5% CO2, 98% humidity for 24 h. The stock solutions were dissolved in DMSO at 2 mg mL−1. The experiment was conducted with various concentrations of samples (128, 32, 8 and 2 μg mL−1) and duplicated for three times.
O) and 1222 cm−1 (C–O). The 1H NMR spectrum of 1 (Table 1) displayed the presence of a β-substituted furan ring [δH 7.82 (1H, s), 7.44 (1H, br s) and 6.77 (1H, s)], a methoxy group (δH 3.67, 3H, s), three acetyl moieties (δH 2.13, 2.11 and 1.93, each 3H, s) and four tertiary methyls (δH 1.34, 1.19, 0.93 and 0.72, each 3H, s). The 13C NMR (Table 2) and HSQC spectra revealed resonances for 33 carbons including a furan ring (δC 143.0, 141.7, 120.4 and 110.2); five carbonyls (δC 175.3, 174.1, 170.6, 169.8 and 169.0); one methoxy; seven non-hydrogenated sp3 carbons comprising those of three monooxygenated tertiary carbons and one hemiacetal carbon (δC 108.9); five methines including three oxygenated ones; four methylenes; and seven methyls with three in the acetyl groups. Analyses of 1H and 13C NMR data, especially the β-furanyl ring, suggested that 1 was a tetranortriterpenoid or a mexicanolide-type limonoid. The planar structure of 1 was demonstrated by elucidation of 1H–1H COSY, HSQC and HMBC spectra. The spectroscopic data of 1 were similar to those of ivorenoid D previously isolated from Khaya ivorensis,25 except for the existence of the hydroxy at C-14 and the acetoxy instead of the hydroxy group attached to C-11 (δC 69.0). The characteristic chemical shifts of C-1 at δC 108.9 and C-8 at δC 81.4 indicated the presence of a 1,8-hemiacetal motif with an ether bridge between C-8 and C-1. The configuration of the 1,8-hemiacetal and substituents on rings A and B has been described in other related mexicanolides.25–27 Additionally, the HMBC correlations from a methine proton (δH 5.06, H-11) and methyl protons (δH 1.93) to a carbonyl carbon (δC 169.8) comprehensively pointed to the acetoxy group bonded to the C-11 position. The presence of an acetoxy group assigned at C-3 was determined by cross-peaks between a methine proton at δH 5.52 (δC 75.7, C-3), methyl protons at δH 2.13 (δC 21.1) and a carbonyl carbon at δC 170.6. Comparison of the chemical shifts of C-1 (δC 108.9), C-2 (δC 94.4) and C-3 (δC 75.7) of compound 1 with those of ivorenoid D indicated that the last acetoxy group was consequently located at the oxygenated tertiary carbon C-2 (δC 94.4). In the NOESY spectrum (Fig. 3), NOE correlations between H3-18 and H-22/Hb-15/Hb-12, between Hb-12 and H-9 revealed the same α orientation of the protons. As a result, the designated β-substituted furan ring attached to C-17 was confirmed to be α-oriented. Therefore, proton H-17 possessed the β-orientation. The cross-peaks of H-17/Ha-30 and Ha-30/H-11 exhibited that these protons were co-facial. Moreover, NOE correlations observed between H-3 and H3-28, H3-28 and Hb-6 indicated that they were α-oriented, and consequently the acetoxy group at C-3 was β-oriented. The compound accordingly had structure 1 which is named swietemicrolide A.
Compound 2 was isolated as small white needles, m.p. 169–171 °C, [α]D25 – 52.1 (c 1.1, MeOH). The UV spectrum showed a maximum at 209 nm and the IR spectrum gave signals at 3446 cm−1 (O–H), 1740 cm−1 (C
O) and 1228 cm−1 (C–O). The 1D (Tables 1 and 2) and 2D (Fig. 2 and 3) NMR spectroscopic data of 2 closely resembled those of 1, suggesting that 2 was also a mexicanolide-type limonoid with a 1,8-hemiacetal system. The significant difference was the absence of an acetoxy group in compound 2. This was in agreement with the HRESIMS spectrum which indicated a deprotonated molecule at m/z 619.2385, which was assigned the molecular formula of C31H40O13 with one less degree of unsaturation in comparison with that of compound 1. Furthermore, the upfield shift of the oxygenated tertiary carbon (δC 81.0, C-2) in the 13C NMR spectrum of 2 implied that the acetoxy group observed in compound 1 was replaced by the hydroxy group. The compound was therefore determined as 2 and is named swietemicrolide B.
Compound 3 was obtained as small white needles, m.p. 152–154 °C, [α]D25 – 56.5 (c 1.1, MeOH). It was assigned the molecular formula of C31H38O12 due to its negative peak at m/z 647.2318 [M + HCOO]− in the HRESIMS spectrum, requiring 13 degrees of unsaturation. The UV spectrum showed a maximum at 208 nm and the IR spectrum had characteristic absorption bands at 3502 cm−1 (O–H), 1741 cm−1 (C
O) and 1234 cm−1 (C–O). The 1H and 13C NMR spectra of 3 (Tables 1 and 2) revealed resonances for a β-substituted furan ring, a methoxy, two acetyls, four tertiary methyls, four methylenes, five methines, five carbonyl carbons, six non-hydrogenated sp3 carbons including two oxygenated tertiary carbons. The spectroscopic features suggested that compound 3 possibly was a limonoid. A comparison of the 1D and 2D NMR of compound 3 with those of grandifotane A22 indicated that they shared the same skeletal structure. Grandifotane A was isolated from Khaya grandifoliola, which was known as the first and the unique mexicanolide-type limonoid bearing grandifotane scaffold. Furthermore, to the best of our knowledge, this is the first time a grandifotane core limonoid has been discovered in the genus Swietenia. The main differences were the presence of the acetoxy group bonded to C-11 (δC 69.0) and the methylene (δH 2.44 and 2.42, δC 32.3, C-6) observed instead of the oxymethine. The methylene was determined by the spin coupling system of H2-6 and H-5 in 1H–1H COSY spectrum combined with the key HMBC correlations from H2-6 to C-5 and C-7 (Fig. 2). The relative configuration of 3 was partially established by the NOESY spectrum (Fig. 3). The NOE correlations of H3-29/H-5, H-5/H-11, H-11/H-17 and H-17/Ha-12 indicated that they were co-facial and had the β-orientation; whereas those of H3-28/H-3, H-3/H3-19, H3-19/H-9, H-9/Hb-12, Hb-12/H3-18 and H3-18/H-22 assigned these in the α-orientation. The interpretation of NOESY spectrum, NMR data and coupling patterns suggested that relative configuration of 3 has been closely related to that of grandifotane A. The compound was consequently determined to have structure 3 namely swietemicrolide C.
Compound 4 was isolated as small white needles, m.p. 210–212 °C, [α]D25 – 167.0 (c 0.5, MeOH), UV: (λmax) 208 and 283 nm, IR: (νmax) 3447 cm−1 (O–H), 1743 cm−1 (C
O) and 1232 cm−1 (C–O), C31H38O11 (m/z 587.2521 [M + H]+) with 13 degrees of unsaturation. The 1D (Tables 1 and 2) and 2D (Fig. 2 and 3) NMR spectroscopic data of 4 shared high similarities with those of compound 3 and grandifotane A,22 corresponding to the grandifotane skeleton. However, in comparison with grandifotane A, compound 4 contained the methine at C-14 (δH 2.35, δC 42.4) and the acetoxy bonded to C-6. The former was supported by the HMBC correlation between the proton at δH 2.35 and carbons in the δ-lactone ring. Meanwhile, the proton H-6 (δH 5.19) correlated to the two carbonyls (δC 170.3 and 170.2). The carbonyl at δC 170.2 showed a cross-peak with methoxy protons (δH 3.79, 3H, s), which was C-7. The remaining carbonyl (δC 170.3) correlated with the methyl protons at δH 2.16, to establish the presence of an acetyl group attached to the oxygenated methine carbon C-6. The correlations observed in the 1H–1H COSY, HMBC (Fig. 2) and NOESY (Fig. 3) spectra further confirmed the structure and the relative configuration of 4. The structure of compound 4 was therefore characterized to be swietemicrolide D.
The possible biosynthetic pathways for 1–4 are proposed in Scheme 1. Fissinolide is likely to be a biogenetic precursor of compounds 1–2, featuring a 1,8-hemiacetal system, and compounds 3–4, which possess a grandifotane scaffold. Hydroxylation at C-11 of fissinolide by a monooxygenase followed by acetylation could result in the formation of iv, which was possibly transformed into v by a dihydroxylation of the Δ8,14 double bond to introduce two vicinal hydroxy groups. Compound v could convert into the key intermediate vi via an intramolecular nucleophilic addition between the ketonic carbonyl (C-1) and the hydroxy at C-8 to yield the 1,8-hemiacetal linkage. The C-2 of vi could undergo a hydroxylation to form compound 2, which is then likely acetylated to give compound 1. The formation pathways of compounds 3 and 4 is proposed according to the plausible biosynthesis of grandifotane A.22 An enzyme-catalyzed Baeyer–Villiger oxidation at the ketonic carbonyl of v would simultaneously result in an ester bridge between C-1 and C-10 in vii, which starts the formation of the unique tricyclodecane ring system. Transesterification followed by protonation of the hydroxy bonded to C-10 and further Wagner–Meerwein rearrangement convert vii via the intermediate viii into compound 3 with the removal of a water molecule to form a bond between C-2 and C-10. Similarly, compound 4 could be possibly formed from fissinolide by undergoing a hydroxylation followed by an acetylation at C-6 to give ix. Hydroxylation at the Δ8,14 double bond could introduce a hydroxy at C-8 (x). The grandifotane skeleton is likely designated as in 3 through several steps via the intermediates xi and xii. The biosynthetic pathway proposal could not only explain the formation of the fused ring systems but also support the relative configuration of 1–4 which are consistent with those of previously reported mexicanolides.22,28
The five limonoids, including swietemicrolides A–D (1–4) and swiemahogin A (5), were evaluated for their in vitro cytotoxicity against two human cancer cell lines, KB epidermal carcinoma and A549 human lung cancer cells using 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay described by Mosmann23 with ellipticine as the positive control (Table 3). Only swietemicrolide C (3) inhibited more than 50% cell growth at the concentration of 128 μg mL−1 and therefore was further tested for the IC50 values and displayed weak activities (IC50 = 174.8 μM and 189.9 μM, respectively). Moreover, they were accessed for their in vitro α-glucosidase inhibitory effects (Table 3).24 As the result, only swietemicrolide C (3) showed potential activity with an IC50 value of 253.6 μM, about three times stronger than the positive control, acarbose (IC50 = 697.7 μM), while the others were found to be completely inactive. The results suggested that the appearance of an acetoxy side chain at C-11 and a hydroxy group at C-14 attached to the grandifotane skeleton increased the effect whilst the presence of an acetoxy group at C-6 could reduce the activity.
Footnotes |
| † Electronic supplementary information (ESI) available: UV, IR, HRESIMS, 1D and 2D NMR spectra for 1–4; 1D NMR spectra for 5–7. See DOI: https://doi.org/10.1039/d4ra01954g |
| ‡ Present address: Dalat University, Da Lat City, Lam Dong Province, Vietnam. |
| This journal is © The Royal Society of Chemistry 2024 |